{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T00:31:16Z","timestamp":1714696276675},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T00:00:00Z","timestamp":1707436800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Busulfan MyCare Oncology"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Busulfan is widely used in conditioning regimens to prepare patients for hematopoietic stem cell transplantation. Therapeutic drug monitoring (TDM) is critical due to large inter- and intra-individual variability in busulfan pharmacokinetics, and the risk of adverse consequences of toxicity including hepatic veno-occlusive disease. Busulfan is most commonly measured by liquid chromatography\u2013mass spectrometry (LC-MS\/MS), which is not as widely available in clinical laboratories as automated routine clinical chemistry analyzers. The objective was to perform analytical verification of a busulfan immunoassay on the Abbott Alinity c platform.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The MyCare Oncology busulfan immunoassay was configured as a third-party reagent on the Abbott Alinity c. Imprecision, linearity, sample carryover, and onboard stability of reagent studies were evaluated. The performance of the busulfan immunoassay using the Abbott Alinity c was compared to the Beckman Coulter AU480 using sodium heparinized plasma, as well as to LC-MS\/MS using lithium heparinized plasma.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The imprecision goal of 8% was met, and linearity within the analytical measurement range of 240 to 1700\u2005ng\/mL was verified. Sample carryover was negligible, and the reagents were stable onboard for at least 84 days. The busulfan immunoassay correlated well with LC-MS\/MS (slope = 0.949, y-intercept = \u22127.8\u2005ng\/mL, r2 = 0.9935) and the Beckman Coulter AU480 (slope = 1.090, y-intercept = \u221234.5\u2005ng\/mL, r2 = 0.9988).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study demonstrated successful analytical verification of a busulfan third-party immunoassay on the Abbott Alinity c platform. The ability to perform TDM of busulfan on a routine clinical chemistry analyzer will positively impact turnaround times to improve patient outcomes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jalm\/jfad134","type":"journal-article","created":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T08:32:48Z","timestamp":1707467568000},"page":"549-557","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of Busulfan as a Third-Party Immunoassay on a Clinical Chemistry Analyzer"],"prefix":"10.1093","volume":"9","author":[{"given":"Janet R","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine and Pathobiology, University of Toronto , Toronto, ON , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"To","sequence":"additional","affiliation":[{"name":"Division of Clinical Biochemistry, University Health Network , Toronto, ON , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Fritz","sequence":"additional","affiliation":[{"name":"Saladax Biomedical, Inc. , Bethlehem, PA , United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Jung","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathobiology, University of Toronto , Toronto, ON , Canada"},{"name":"Division of Clinical Biochemistry, Department of Paediatric Laboratory Medicine, Hospital for Sick Children , Toronto, ON , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehrdad","family":"Yazdanpanah","sequence":"additional","affiliation":[{"name":"Division of Clinical Biochemistry, Department of Paediatric Laboratory Medicine, Hospital for Sick Children , Toronto, ON , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vathany","family":"Kulasingam","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathobiology, University of Toronto , Toronto, ON , Canada"},{"name":"Division of Clinical Biochemistry, University Health Network , Toronto, ON , Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,2,9]]},"reference":[{"key":"2024050218421092900_jfad134-B1","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0140-6736(53)90884-8","article-title":"Myleran in chronic myeloid leukaemia; chemical constitution and biological action","volume":"264","author":"Haddow","year":"1953","journal-title":"Lancet"},{"key":"2024050218421092900_jfad134-B2","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1056\/NEJM198312013092202","article-title":"Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide","volume":"309","author":"Santos","year":"1983","journal-title":"N Engl J Med"},{"key":"2024050218421092900_jfad134-B3","doi-asserted-by":"crossref","first-page":"1015200","DOI":"10.3389\/fonc.2022.1015200","article-title":"Therapeutic drug monitoring for cytotoxic anticancer drugs: principles and evidence-based practices","volume":"12","author":"Smita","year":"2022","journal-title":"Front Oncol"},{"key":"2024050218421092900_jfad134-B4"},{"key":"2024050218421092900_jfad134-B5","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/sj.bmt.1703612","article-title":"Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation","volume":"30","author":"McCune","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"2024050218421092900_jfad134-B6","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1182\/blood.V89.8.3055","article-title":"Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation","volume":"89","author":"Slattery","year":"1997","journal-title":"Blood"},{"key":"2024050218421092900_jfad134-B7","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.bbmt.2008.11.022","article-title":"Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematologic stem cell transplantation","volume":"15","author":"Bartelink","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"2024050218421092900_jfad134-B8","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1093\/clinchem\/44.12.2506","article-title":"Routine analysis of plasma busulfan by gas chromatography-mass fragmentography","volume":"44","author":"Lai","year":"1998","journal-title":"Clin Chem"},{"key":"2024050218421092900_jfad134-B9","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/clinchem\/47.8.1437","article-title":"Sensitive and rapid quantification of busulfan in small plasma volumes by liquid chromatography-electrospray mass spectrometry","volume":"47","author":"M\u00fcrdter","year":"2001","journal-title":"Clin Chem"},{"key":"2024050218421092900_jfad134-B10","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/01.ftd.0000173372.04945.7b","article-title":"Tandem mass spectrometry method for the quantification of serum busulfan","volume":"27","author":"Kellogg","year":"2005","journal-title":"Ther Drug Monit"},{"key":"2024050218421092900_jfad134-B11","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0378-4347(98)00473-3","article-title":"High-performance liquid chromatographic method for quantification of busulfan in plasma after derivatization by tetrafluorothiophenol","volume":"721","author":"Quernin","year":"1999","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"2024050218421092900_jfad134-B12","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0378-4347(99)00214-5","article-title":"Determination of busulfan in human plasma using high-performance liquid chromatography with pre-column derivatization and fluorescence detection","volume":"730","author":"Peris","year":"1999","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"2024050218421092900_jfad134-B13","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1093\/clinchem\/47.4.766","article-title":"Stability of busulfan in frozen plasma and whole blood samples","volume":"47","author":"Balasubramanian","year":"2001","journal-title":"Clin Chem"},{"key":"2024050218421092900_jfad134-B14","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1097\/FTD.0000000000000883","article-title":"Evaluation of a nanoparticle-based busulfan immunoassay for rapid analysis on routine clinical analyzers","volume":"43","author":"Hilaire","year":"2021","journal-title":"Ther Drug Monit"},{"key":"2024050218421092900_jfad134-B15","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/FTD.0000000000000933","article-title":"Automation in busulfan therapeutic drug monitoring: evaluation of an immunoassay on two routine chemistry analyzers","volume":"44","author":"Verougstraete","year":"2022","journal-title":"Ther Drug Monit"},{"key":"2024050218421092900_jfad134-B16","volume-title":"Evaluation of precision of quantitative measurement procedures; approved guideline third edition. CLSI document EP05-A3","author":"CLSI","year":"2014"},{"key":"2024050218421092900_jfad134-B17","volume-title":"Evaluation of linearity of quantitative measurement procedures. CLSI document EP06","author":"CLSI","year":"2020"}],"container-title":["The Journal of Applied Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jalm\/article-pdf\/9\/3\/549\/57388925\/jfad134.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jalm\/article-pdf\/9\/3\/549\/57388925\/jfad134.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T18:43:52Z","timestamp":1714675432000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jalm\/article\/9\/3\/549\/7604025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,9]]},"references-count":17,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,2,9]]},"published-print":{"date-parts":[[2024,5,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jalm\/jfad134","relation":{},"ISSN":["2475-7241"],"issn-type":[{"value":"2475-7241","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5]]},"published":{"date-parts":[[2024,2,9]]}}}